4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer

13 Apr 2023 05:00:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights

15 Mar 2023 13:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™

22 Feb 2023 13:05:00 By Nasdaq GlobeNewswire

4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™

16 Feb 2023 13:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference

08 Feb 2023 13:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

02 Feb 2023 13:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference

21 Nov 2022 13:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

14 Nov 2022 04:30:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022

10 Nov 2022 13:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results

09 Nov 2022 13:05:02 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022

03 Nov 2022 06:45:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022

26 Oct 2022 13:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer

27 Sep 2022 13:10:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

20 Sep 2022 13:15:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update

11 Aug 2022 13:03:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences

02 Jun 2022 13:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

12 May 2022 13:01:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

05 May 2022 13:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis

04 Apr 2022 13:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

28 Mar 2022 13:02:00 By Nasdaq GlobeNewswire